TWI804044B - Btla同效劑抗體及其用途 - Google Patents

Btla同效劑抗體及其用途 Download PDF

Info

Publication number
TWI804044B
TWI804044B TW110141711A TW110141711A TWI804044B TW I804044 B TWI804044 B TW I804044B TW 110141711 A TW110141711 A TW 110141711A TW 110141711 A TW110141711 A TW 110141711A TW I804044 B TWI804044 B TW I804044B
Authority
TW
Taiwan
Prior art keywords
ser
seq
leu
val
antibody
Prior art date
Application number
TW110141711A
Other languages
English (en)
Chinese (zh)
Other versions
TW202233681A (zh
Inventor
夏尼 克魯曼 艾特威爾
維特 H 歐邦谷
安德魯 查爾斯 凡朵
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202233681A publication Critical patent/TW202233681A/zh
Application granted granted Critical
Publication of TWI804044B publication Critical patent/TWI804044B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110141711A 2017-05-19 2018-05-04 Btla同效劑抗體及其用途 TWI804044B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
US62/508,510 2017-05-19

Publications (2)

Publication Number Publication Date
TW202233681A TW202233681A (zh) 2022-09-01
TWI804044B true TWI804044B (zh) 2023-06-01

Family

ID=62245543

Family Applications (4)

Application Number Title Priority Date Filing Date
TW110141711A TWI804044B (zh) 2017-05-19 2018-05-04 Btla同效劑抗體及其用途
TW107115166A TWI677504B (zh) 2017-05-19 2018-05-04 Btla同效劑抗體及其用途
TW108133289A TWI747043B (zh) 2017-05-19 2018-05-04 Btla同效劑抗體及其用途
TW112116965A TW202334237A (zh) 2017-05-19 2018-05-04 Btla同效劑抗體及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW107115166A TWI677504B (zh) 2017-05-19 2018-05-04 Btla同效劑抗體及其用途
TW108133289A TWI747043B (zh) 2017-05-19 2018-05-04 Btla同效劑抗體及其用途
TW112116965A TW202334237A (zh) 2017-05-19 2018-05-04 Btla同效劑抗體及其用途

Country Status (26)

Country Link
US (2) US10604573B2 (enExample)
EP (1) EP3625257A1 (enExample)
JP (2) JP6790304B2 (enExample)
KR (3) KR102294051B1 (enExample)
CN (3) CN110621699B (enExample)
AR (1) AR111752A1 (enExample)
AU (2) AU2018269585B2 (enExample)
BR (1) BR112019021547A2 (enExample)
CA (2) CA3184628A1 (enExample)
CL (1) CL2019003215A1 (enExample)
CO (1) CO2019012756A2 (enExample)
CR (1) CR20190521A (enExample)
DO (1) DOP2019000293A (enExample)
EA (1) EA201992460A1 (enExample)
EC (1) ECSP19082184A (enExample)
JO (1) JOP20190261A1 (enExample)
MA (1) MA49133A (enExample)
MX (1) MX381033B (enExample)
MY (2) MY197425A (enExample)
NZ (1) NZ758360A (enExample)
PE (1) PE20191843A1 (enExample)
PH (1) PH12019502575A1 (enExample)
SA (1) SA519410534B1 (enExample)
TW (4) TWI804044B (enExample)
WO (1) WO2018213113A1 (enExample)
ZA (1) ZA201906954B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
IL302135A (en) * 2020-10-23 2023-06-01 Anaptysbio Inc B and t lymphocyte attenuator (btla) modulators and method of using same
MX2024009326A (es) * 2022-01-29 2024-08-06 Hifibio Inc Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014438A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2016176583A1 (en) * 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (en) * 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2669921A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
JP7227007B2 (ja) * 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014438A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2016176583A1 (en) * 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies

Also Published As

Publication number Publication date
JOP20190261A1 (ar) 2019-11-05
TW201946932A (zh) 2019-12-16
JP2021019642A (ja) 2021-02-18
KR20210106033A (ko) 2021-08-27
AU2018269585B2 (en) 2021-09-02
US20200239578A1 (en) 2020-07-30
AU2018269585A1 (en) 2019-10-31
CN110621699A (zh) 2019-12-27
TWI747043B (zh) 2021-11-21
KR102294051B1 (ko) 2021-08-27
CA3184628A1 (en) 2018-11-22
CL2019003215A1 (es) 2020-04-13
US20180334502A1 (en) 2018-11-22
TW202334237A (zh) 2023-09-01
JP2020518288A (ja) 2020-06-25
MY198277A (en) 2023-08-18
CO2019012756A2 (es) 2020-01-17
KR20220158847A (ko) 2022-12-01
CN117402245A (zh) 2024-01-16
TW201904991A (zh) 2019-02-01
PE20191843A1 (es) 2019-12-31
ZA201906954B (en) 2021-06-30
MY197425A (en) 2023-06-16
MX2019013604A (es) 2019-12-18
MA49133A (fr) 2020-03-25
DOP2019000293A (es) 2019-12-15
CN110621699B (zh) 2023-10-31
EA201992460A1 (ru) 2020-03-18
SA519410534B1 (ar) 2023-11-08
AR111752A1 (es) 2019-08-14
JP6790304B2 (ja) 2020-11-25
ECSP19082184A (es) 2019-11-30
PH12019502575A1 (en) 2020-07-13
BR112019021547A2 (pt) 2020-05-12
KR20190140969A (ko) 2019-12-20
TW202233681A (zh) 2022-09-01
US11396545B2 (en) 2022-07-26
US10604573B2 (en) 2020-03-31
JP7072622B2 (ja) 2022-05-20
CN117402244A (zh) 2024-01-16
CR20190521A (es) 2020-01-06
TWI677504B (zh) 2019-11-21
CA3064518A1 (en) 2018-11-22
MX381033B (es) 2025-03-12
NZ758360A (en) 2022-10-28
EP3625257A1 (en) 2020-03-25
WO2018213113A1 (en) 2018-11-22
AU2021277743A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
TWI804044B (zh) Btla同效劑抗體及其用途
CN112513091B (zh) 抗il36r抗体
KR102772851B1 (ko) Trem2 항원 결합 단백질 및 이의 용도
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
KR102025848B1 (ko) 항―ｎｇｆ 조성물 및 그의 용도
US9708402B2 (en) Anti-BAFF-anti-IL-17 bispecific antibodies
CN107531783B (zh) 靶向bmp6抗体的组合物和方法
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
TW201023890A (en) Antagonists of IL-6 to prevent or thrombosis
AU2014226093A1 (en) Anti-TNF-anti-IL-17 bispecific antibodies
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
KR20090088950A (ko) 가공된 항-ｔｓｌｐ 항체
AU2019339334B2 (en) CD200R agonist antibodies and uses thereof
KR20210031722A (ko) 산성 pH에서 VISTA에 결합하는 항체
CN113015557B (zh) 抗alpha-突触核蛋白抗体及其用途
KR20240004694A (ko) 항체
CN111918879B (zh) 用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白
KR102895164B1 (ko) 항-il36r 항체
HK40016006A (en) Trem2 antigen binding proteins and uses thereof